Clinical Trial Update: Paricalcitol in Reducing Parathyroid Hormone Levels and Ameliorating Markers of Bone Remodelling in Renal Transplant Recipients With Secondary Hyperparathyroidism [Phase 2]

View source ↗

Summary

Phase 2 trial assessing paricalcitol's ability to lower parathyroid hormone levels and improve bone remodeling markers in renal transplant recipients with secon…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• Hyperparathyroidism

Drugs mentioned

• Paricalcitol (paricalcitol)

Snippet

Sponsor: Mario Negri Institute for Pharmacological Research | Conditions: Renal Transplant, Secondary Hyperparathyroidism | Phase 2 | Status: COMPLETED